A detailed history of Manufacturers Life Insurance Company, The transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 54,522 shares of IRWD stock, worth $245,894. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,522
Previous 77,074 29.26%
Holding current value
$245,894
Previous $502,000 55.38%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.93 - $7.04 $88,629 - $158,766
-22,552 Reduced 29.26%
54,522 $224,000
Q2 2024

Aug 14, 2024

SELL
$5.58 - $8.61 $16,812 - $25,941
-3,013 Reduced 3.76%
77,074 $502,000
Q1 2024

May 14, 2024

BUY
$8.32 - $15.45 $68,548 - $127,292
8,239 Added 11.47%
80,087 $697,000
Q4 2023

Feb 13, 2024

SELL
$8.79 - $11.51 $2,724 - $3,568
-310 Reduced 0.43%
71,848 $821,000
Q3 2023

Nov 15, 2023

BUY
$8.25 - $11.35 $131,216 - $180,521
15,905 Added 28.27%
72,158 $694,000
Q2 2023

Aug 11, 2023

BUY
$10.1 - $11.6 $18,190 - $20,891
1,801 Added 3.31%
56,253 $598,000
Q1 2023

May 15, 2023

BUY
$10.37 - $12.56 $3,847 - $4,659
371 Added 0.68%
54,823 $576,000
Q4 2022

Aug 11, 2023

SELL
$9.9 - $12.43 $673 - $845
-68 Reduced 0.12%
54,452 $674,000
Q4 2022

Feb 13, 2023

SELL
$9.9 - $12.43 $673 - $845
-68 Reduced 0.12%
54,452 $674,000
Q3 2022

Aug 11, 2023

SELL
$10.14 - $12.38 $8,182 - $9,990
-807 Reduced 1.46%
54,520 $564,000
Q3 2022

Nov 03, 2022

SELL
$10.14 - $12.38 $8,182 - $9,990
-807 Reduced 1.46%
54,520 $565,000
Q2 2022

Aug 11, 2023

SELL
$11.05 - $12.72 $52,995 - $61,005
-4,796 Reduced 7.98%
55,327 $637,000
Q2 2022

Aug 15, 2022

SELL
$11.05 - $12.72 $52,995 - $61,005
-4,796 Reduced 7.98%
55,327 $638,000
Q1 2022

Aug 11, 2023

BUY
$10.61 - $12.88 $56,233 - $68,264
5,300 Added 9.67%
60,123 $756,000
Q1 2022

May 20, 2022

SELL
$10.61 - $12.88 $153,898 - $186,824
-14,505 Reduced 19.44%
60,123 $756,000
Q4 2021

Feb 16, 2022

SELL
$10.86 - $13.95 $13,900 - $17,856
-1,280 Reduced 1.69%
74,628 $870,000
Q3 2021

Nov 12, 2021

SELL
$11.92 - $13.92 $73,796 - $86,178
-6,191 Reduced 7.54%
75,908 $991,000
Q2 2021

Aug 12, 2021

SELL
$10.16 - $13.11 $88,026 - $113,585
-8,664 Reduced 9.55%
82,099 $1.06 Million
Q1 2021

May 03, 2021

SELL
$9.04 - $11.86 $45,362 - $59,513
-5,018 Reduced 5.24%
90,763 $1.02 Million
Q4 2020

Feb 12, 2021

BUY
$9.05 - $12.2 $24,217 - $32,647
2,676 Added 2.87%
95,781 $1.09 Million
Q3 2020

Nov 09, 2020

SELL
$8.99 - $10.74 $20,119 - $24,036
-2,238 Reduced 2.35%
93,105 $837,000
Q2 2020

Aug 10, 2020

SELL
$9.14 - $11.97 $32,401 - $42,433
-3,545 Reduced 3.58%
95,343 $971,000
Q1 2020

May 15, 2020

BUY
$8.58 - $14.01 $51,565 - $84,200
6,010 Added 6.47%
98,888 $998,000
Q4 2019

Feb 14, 2020

SELL
$8.22 - $14.0 $26,509 - $45,150
-3,225 Reduced 3.36%
92,878 $1.24 Million
Q3 2019

Nov 12, 2019

SELL
$8.59 - $10.96 $3,496 - $4,460
-407 Reduced 0.42%
96,103 $841,000
Q2 2019

Aug 14, 2019

BUY
$9.8 - $12.89 $41,316 - $54,344
4,216 Added 4.57%
96,510 $1.06 Million
Q1 2019

May 13, 2019

BUY
$8.27 - $12.73 $42,979 - $66,157
5,197 Added 5.97%
92,294 $1.05 Million
Q4 2018

Feb 14, 2019

SELL
$7.8 - $16.13 $27,206 - $56,261
-3,488 Reduced 3.85%
87,097 $903,000
Q3 2018

Nov 14, 2018

SELL
$14.31 - $17.65 $174,753 - $215,541
-12,212 Reduced 11.88%
90,585 $1.67 Million
Q2 2018

Aug 14, 2018

BUY
$11.83 - $16.2 $27,067 - $37,065
2,288 Added 2.28%
102,797 $1.97 Million
Q1 2018

May 15, 2018

SELL
$11.13 - $13.63 $32,866 - $40,249
-2,953 Reduced 2.85%
100,509 $1.55 Million
Q4 2017

Feb 08, 2018

BUY
$12.16 - $14.58 $4,024 - $4,825
331 Added 0.32%
103,462 $1.55 Million
Q3 2017

Nov 14, 2017

BUY
$12.07 - $14.87 $1.24 Million - $1.53 Million
103,131
103,131 $1.63 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $691M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.